<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17097" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Acinetobacter</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brady</surname>
            <given-names>Mark F.</given-names>
          </name>
          <aff>Alpert Medical School of Brown University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jamal</surname>
            <given-names>Zohaib</given-names>
          </name>
          <aff>Rawalpindi Medical University, Rawalpindi</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pervin</surname>
            <given-names>Najwa</given-names>
          </name>
          <aff>Southern Illinois University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Brady declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zohaib Jamal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Najwa Pervin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17097.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p><italic toggle="yes">Acinetobacter</italic> is a gram-negative, nonmotile organism that is often found in soil and water and is known to colonize intravenous fluids. In general, <italic toggle="yes">Acinetobacter</italic> has low virulence. However, it is capable of causing infection in immunocompromised and neutropenic patients, and it is becoming increasingly drug-resistant. The morbidity and mortality of <italic toggle="yes">Acinetobacter</italic> is high in sick patients with multi-organ disease. In the case of infections caused by resistant strains of <italic toggle="yes">Acinetobacter baumannii</italic>, mortality rates of up to 70% have been reported. Most <italic toggle="yes">Acinetobacter</italic> isolates obtained result from nosocomial spread and colonization rather than de novo infections. Since isolated Acinetobacter infections are rare and most <italic toggle="yes">Acinetobacter</italic> infections correspond to group outbreaks, patients colonized with <italic toggle="yes">Acinetobacter</italic> should be isolated from other patients to prevent further colonization. This activity reviews the etiology and epidemiology of <italic toggle="yes">Acinetobacter</italic> colonization and infection and provides recommendations on treatment and management. This activity highlights the role of the interprofessional team in caring for patients colonized or infected with this organism.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify some of the organ systems affected by <italic toggle="yes">Acinetobacter</italic> infections.</p></list-item><list-item><p>Describe the management of a patient who is colonized by <italic toggle="yes">Acinetobacter</italic>, and discuss how this might change if the patient is thought to have an infection caused by <italic toggle="yes">Acinetobacter</italic>.</p></list-item><list-item><p>Recognize when the infection control team should be made aware of the presence of <italic toggle="yes">Acinetobacter</italic> isolates.</p></list-item><list-item><p>Describe the importance of coordination and communication amongst the interprofessional team members when caring for patients colonized or infected by organisms which have the potential to cause outbreaks.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17097&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17097">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17097.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p><italic toggle="yes">Acinetobacter</italic> is a gram-negative, aerobic, non-fermentative, oxidase-negative, and nonmotile organism.<xref ref-type="bibr" rid="article-17097.r1">[1]</xref>
<italic toggle="yes">Acinetobacter</italic> has several species, but<italic toggle="yes"> A. baumannii</italic> has the greatest clinical significance.<xref ref-type="bibr" rid="article-17097.r2">[2]</xref>
<italic toggle="yes">Acinetobacter</italic> can be found in soil and water. Patients are frequently cultured from urine, saliva, respiratory secretions, and open wounds. The organism is also known to colonize intravenous fluids and other irrigation solutions.<xref ref-type="bibr" rid="article-17097.r3">[3]</xref><xref ref-type="bibr" rid="article-17097.r4">[4]</xref></p>
        <p>In general,&#x000a0;<italic toggle="yes">Acinetobacter</italic> has low virulence but is capable of causing infection in immunocompromised and neutropenic patients. Most of the infections are a result of nosocomial spread and colonization rather than de novo infections. Thus, great care is required when Acinetobacter is isolated - whether it is an actual infection or colonization. Risk factors for <italic toggle="yes">Acinetobacter</italic> infection include:</p>
        <list list-type="order">
          <list-item>
            <p>Prolonged stay in the intensive care unit</p>
          </list-item>
          <list-item>
            <p>Prolonged antibiotic exposure&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mechanical ventilation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Use of a central venous catheter</p>
          </list-item>
          <list-item>
            <p>Hemodialysis<xref ref-type="bibr" rid="article-17097.r5">[5]</xref><xref ref-type="bibr" rid="article-17097.r6">[6]</xref><xref ref-type="bibr" rid="article-17097.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>Most <italic toggle="yes">Acinetobacter</italic> infections are group outbreaks, and isolated cases are rare. Infections may complicate intravenous (IV) catheter treatment, mechanical ventilation, and even peritoneal dialysis. In most cases, the presence of&#x000a0;<italic toggle="yes">Acinetobacter</italic> in the respiratory secretions of ventilated patients represents colonization.</p>
      </sec>
      <sec id="article-17097.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Even though <italic toggle="yes">Acinetobacter</italic> is mostly a nosocomial pathogen and is isolated from hospitalized patients, care should be exercised in determining if the isolate is a cause or simply&#x000a0;a result of colonization. <italic toggle="yes">Acinetobacter</italic> is a water-loving organism and has the propensity to colonize body organs that contain fluid. Thus, in hospitalized patients, <italic toggle="yes">Acinetobacter</italic> is often found in the peritoneal fluid, cerebrospinal fluid (CSF), saliva, respiratory secretions and urinary tract.<xref ref-type="bibr" rid="article-17097.r8">[8]</xref><xref ref-type="bibr" rid="article-17097.r9">[9]</xref></p>
      </sec>
      <sec id="article-17097.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p><italic toggle="yes">Acinetobacter</italic> gained clinical significance in the 1960s with the increasing growth of Intensive care units at hospitals.<xref ref-type="bibr" rid="article-17097.r10">[10]</xref>&#x000a0;Though <italic toggle="yes">Acinetobacter</italic> is an organism of low virulence, its ability to survive desiccation and persist in the environment for an extended duration of time makes it easily transmissible in the healthcare setting. Nosocomial spread by healthcare personnel, respiratory equipment like ventilators, and other devices has been reported frequently.&#x000a0;It can be found in all types of secretions, such as wounds, saliva, urine, and blood. The organism has low virulence but is still capable of causing infections in patients with febrile neutropenia and those who have received organ transplants.<xref ref-type="bibr" rid="article-17097.r11">[11]</xref></p>
        <p><italic toggle="yes">Acinetobacter</italic> has also been recognized in wounds sustained by combat injuries in returning soldiers from Iraq and Afghanistan.</p>
        <p>
<bold>Mortality/Morbidity</bold>
</p>
        <p>The&#x000a0;morbidity of this organism is related to the patient's underlying medical condition and immune status. The organism is not very virulent, but due to various innate mechanisms, it has the capacity to acquire resistance. Multidrug-resistant, extensively drug-resistant, and pan-drug-resistant isolates of <italic toggle="yes">Acinetobacter</italic> have been described as non-susceptible to at least one agent in three or more antibiotic classes, non-susceptible to at least one agent in all but two or fewer antibiotic classes and non-susceptible to all antibiotic classes. Multi-drug resistant <italic toggle="yes">Acinetobacter</italic> was designated a threat category of &#x02018;Serious&#x02019; in the Centers for Disease Control antimicrobial resistance report published in 2013. Though not virulent by itself, the morbidity and mortality of <italic toggle="yes">Acinetobacter</italic> are high in sick patients with multiorgan disease. In the case of infections being caused by resistant strains of A.baumanii, mortality rates of up to 70% have been reported. <xref ref-type="bibr" rid="article-17097.r10">[10]</xref></p>
      </sec>
      <sec id="article-17097.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Various mechanisms contribute to the pathogenesis and virulence of <italic toggle="yes">Acinetobacter. Acinetobacter</italic> elaborate on lipopolysaccharide (LPS) or lipooligosaccharide (LOS) in their outer membranes.<xref ref-type="bibr" rid="article-17097.r12">[12]</xref> Modification in the synthesis of these structures imparts antibiotic resistance and increased resistance desiccation.<xref ref-type="bibr" rid="article-17097.r13">[13]</xref>
<italic toggle="yes">Acinetobacter</italic> species also have Capsules that protect them from complement-mediated killing.<xref ref-type="bibr" rid="article-17097.r14">[14]</xref> Pili on the surface of <italic toggle="yes">Acinetobacter</italic> contribute to its twitching motility, biofilm formation, and adherence to environmental surfaces.<xref ref-type="bibr" rid="article-17097.r13">[13]</xref>
<italic toggle="yes">Acinetobacter</italic> also secretes various proteins that lead to antibiotic resistance by efflux or degradation.<xref ref-type="bibr" rid="article-17097.r15">[15]</xref></p>
      </sec>
      <sec id="article-17097.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The infection caused by <italic toggle="yes">Acinetobacter</italic> is similar in histopathology to any other gram-negative bacilli. Gross or microscopic observation does not provide any clue to the organism, and culture is required to confirm the diagnosis.<xref ref-type="bibr" rid="article-17097.r16">[16]</xref></p>
      </sec>
      <sec id="article-17097.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Prolonged hospitalization or antibiotic therapy predisposes to <italic toggle="yes">Acinetobacter</italic> colonization, and because colonization is the rule and infection is the exception, colonized patients have no physical findings.</p>
        <p>Most patients are in the hospital when infected with <italic toggle="yes">Acinetobacter</italic>. The one organ most commonly involved is the lung, primarily because of the colonization of the airways and respiratory equipment used for mechanical ventilation.</p>
        <p>Pneumonia, wound infection, catheter-associated bacteremia, or nosocomial meningitis have all been described by <italic toggle="yes">Acinetobacter</italic>.<xref ref-type="bibr" rid="article-17097.r17">[17]</xref></p>
        <p>There are no pathognomic findings in <italic toggle="yes">Acinetobacter</italic> infections, and they need to be differentiated from other gram-negative infections like <italic toggle="yes">Enterobacter, Burkholderia, Pseudomonas, </italic>and <italic toggle="yes">Serratia. Since Acinetobacter</italic> is chiefly a colonizing organism, the physician has the onus to prove that it is causing the pathology in any given clinical scenario.</p>
      </sec>
      <sec id="article-17097.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p><italic toggle="yes">Acinetobacter</italic> is a common colonizer of patients in the intensive care unit and those who have multiple comorbid disorders. It is most likely to cause infections in patients who are immunocompromised and those with a compromise of their cardiopulmonary system. The organism can readily be cultured, but the findings need to be correlated to the clinical picture.</p>
        <p>
<bold>Laboratory Studies</bold>
</p>
        <p>There may be leukocytosis with a left shift.<xref ref-type="bibr" rid="article-17097.r18">[18]</xref> However, the findings are nonspecific and do not always indicate the presence of&#x000a0;a bacterial infection. When there is an outbreak of <italic toggle="yes">Acinetobacter</italic>, the organism is usually readily isolated and cultured from body fluids. More importantly, the outbreak usually involves multiple patients.</p>
        <p>
<bold>Imaging Studies</bold>
</p>
        <p>A chest x-ray is required if pneumonia is suspected. Other imaging tests depend on signs and symptoms.</p>
        <p>
<bold>Procedures</bold>
</p>
        <p>If meningitis is suspected, then CSF needs to be analyzed and cultured.</p>
        <p>
<bold>Histologic Findings</bold>
</p>
        <p>There are no specific histopathological features of an <italic toggle="yes">Acinetobacter</italic> infection that can differentiate it from any other gram-negative bacilli.</p>
      </sec>
      <sec id="article-17097.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p><italic toggle="yes">Acinetobacter</italic>&#x000a0;is multidrug resistant. Cephalosporins, macrolides, and penicillins have little or no anti-<italic toggle="yes">Acinetobacter</italic> activity. Use of these drugs may predispose the&#x000a0;<italic toggle="yes">Acinobacter</italic>&#x000a0;infection. When an infection is suspected in the presence of a long-term catheter or a pacemaker, it should be removed.<xref ref-type="bibr" rid="article-17097.r19">[19]</xref></p>
        <p>Any external device, infected line, shunt, or drain must be removed to obtain a cure.<xref ref-type="bibr" rid="article-17097.r19">[19]</xref> If the patient has a collection of an abscess or necrotic tissue, it needs to be debrided thoroughly.</p>
        <p>One should avoid treating colonization as it only leads to more antibiotic resistance.</p>
        <p>Over the last few years, drug resistance has become a common problem in the United States. Medications that may be effective include meropenem, sulbactam/durlobactam, colistin, polymyxin B, and amikacin. Alternatives include minocycline, rifampin, and tigecycline.&#x000a0;Monotherapy is standard, as combination therapy has not been shown to be more effective. The duration of therapy is from 7 to 10 days, depending on the patient's illness.</p>
      </sec>
      <sec id="article-17097.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Burkholderia cepacia</italic> infection</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Catheter-associated bacteremia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Enterobacter</italic> species</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Flavobacterium meningosepticum</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nosocomial meningitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pneumonia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Pseudomonas aeruginosa</italic> infection</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Serratia marcescensn </italic>infection</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Stenotrophomonas maltophilia</italic> infection</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Wound infection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17097.s11" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Patients in the intensive care unit are the most difficult to treat as colonization is common, and it is difficult to distinguish this from an infection. All patients noted to have colonization with <italic toggle="yes">Acinetobacter</italic> should be isolated from other patients to prevent further colonization. Once an infection&#x000a0;is treated, the patient's clinical course must be followed rather than cultures because colonization may offer a falsely positive diagnosis.</p>
        <p>The prognosis of an isolated <italic toggle="yes">Acinetobacter</italic> infection is excellent in patients who are otherwise healthy. Immunosuppressed patients tend to&#x000a0;have poor outcomes.</p>
      </sec>
      <sec id="article-17097.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Over the past decade, <italic toggle="yes">Acinetobacter</italic> infections have become common in hospitalized patients. Since this organism can infect almost any organ system, an interprofessional approach to diagnosis and management is essential. The organism is often difficult to isolate because of colonization, so an infectious disease consult should be obtained. Infection control teams should be involved earlier on to prevent outbreaks and utilize ways to prevent nosocomial transmission by eradication of bacteria and strict isolation techniques. The outcomes for most patients with <italic toggle="yes">Acinetobacter</italic> infection are excellent as long as there is no other comorbidity. However, those with immunosuppression may have a guarded prognosis.</p>
        <p>Management should involve a coordinated effort of nurses, pharmacists, and clinicians.</p>
      </sec>
      <sec id="article-17097.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17097&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17097">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/acinetobacter/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17097">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17097/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17097">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17097.s14">
        <title>References</title>
        <ref id="article-17097.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Hartman</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Westblade</surname>
                <given-names>LF</given-names>
              </name>
            </person-group>
            <article-title><italic>Acinetobacter radioresistens</italic> infection with bacteremia and pneumonia.</article-title>
            <source>IDCases</source>
            <year>2019</year>
            <volume>15</volume>
            <fpage>e00495</fpage>
            <pub-id pub-id-type="pmid">30906692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antunes</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Visca</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Towner</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Acinetobacter baumannii: evolution of a global pathogen.</article-title>
            <source>Pathog Dis</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>292</fpage>
            <page-range>292-301</page-range>
            <pub-id pub-id-type="pmid">24376225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eze</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Chenia</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>El Zowalaty</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title><italic>Acinetobacter baumannii</italic> biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments.</article-title>
            <source>Infect Drug Resist</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>2277</fpage>
            <page-range>2277-2299</page-range>
            <pub-id pub-id-type="pmid">30532562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munier</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Biard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Legrand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rousseau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lafaurie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Donay</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Flicoteaux</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mebazaa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mimoun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit.</article-title>
            <source>Int J Infect Dis</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>79</volume>
            <fpage>179</fpage>
            <page-range>179-184</page-range>
            <pub-id pub-id-type="pmid">30529108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maragakis</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Perl</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.</article-title>
            <source>Clin Infect Dis</source>
            <year>2008</year>
            <month>Apr</month>
            <day>15</day>
            <volume>46</volume>
            <issue>8</issue>
            <fpage>1254</fpage>
            <page-range>1254-63</page-range>
            <pub-id pub-id-type="pmid">18444865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Playford</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Iredell</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences.</article-title>
            <source>J Hosp Infect</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>65</volume>
            <issue>3</issue>
            <fpage>204</fpage>
            <page-range>204-11</page-range>
            <pub-id pub-id-type="pmid">17254667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>YP</given-names>
              </name>
            </person-group>
            <article-title>Prior use of four invasive procedures increases the risk of Acinetobacter baumannii nosocomial bacteremia among patients in intensive care units: a systematic review and meta-analysis.</article-title>
            <source>Int J Infect Dis</source>
            <year>2014</year>
            <month>May</month>
            <volume>22</volume>
            <fpage>25</fpage>
            <page-range>25-30</page-range>
            <pub-id pub-id-type="pmid">24607429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garnacho-Montero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Timsit</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Managing Acinetobacter baumannii infections.</article-title>
            <source>Curr Opin Infect Dis</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-76</page-range>
            <pub-id pub-id-type="pmid">30520737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giacobbe</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Mikulska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viscoli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>1219</fpage>
            <page-range>1219-1236</page-range>
            <pub-id pub-id-type="pmid">30444147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Pantapalangkoor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Luna</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Spellberg</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>409</fpage>
            <page-range>409-447</page-range>
            <pub-id pub-id-type="pmid">27974412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Azevedo</surname>
                <given-names>FKSF</given-names>
              </name>
              <name>
                <surname>Dutra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nakazato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mello</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Pepato</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>de Sousa</surname>
                <given-names>ATHI</given-names>
              </name>
              <name>
                <surname>Takahara</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Souto</surname>
                <given-names>FJD</given-names>
              </name>
            </person-group>
            <article-title>Molecular epidemiology of multidrug-resistant Acinetobacter baumannii infection in two hospitals in Central Brazil: the role of ST730 and ST162 in clinical outcomes.</article-title>
            <source>J Med Microbiol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-40</page-range>
            <pub-id pub-id-type="pmid">30516469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Biology of <italic>Acinetobacter baumannii</italic>: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.</article-title>
            <source>Front Cell Infect Microbiol</source>
            <year>2017</year>
            <volume>7</volume>
            <fpage>55</fpage>
            <pub-id pub-id-type="pmid">28348979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harding</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hennon</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Uncovering the mechanisms of Acinetobacter baumannii virulence.</article-title>
            <source>Nat Rev Microbiol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-102</page-range>
            <pub-id pub-id-type="pmid">29249812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lees-Miller</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Iwashkiw</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Seper</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vinogradov</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schild</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>A common pathway for O-linked protein-glycosylation and synthesis of capsule in Acinetobacter baumannii.</article-title>
            <source>Mol Microbiol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>89</volume>
            <issue>5</issue>
            <fpage>816</fpage>
            <page-range>816-30</page-range>
            <pub-id pub-id-type="pmid">23782391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Pathogenic Acinetobacter: from the Cell Surface to Infinity and Beyond.</article-title>
            <source>J Bacteriol</source>
            <year>2015</year>
            <month>Dec</month>
            <day>28</day>
            <volume>198</volume>
            <issue>6</issue>
            <fpage>880</fpage>
            <page-range>880-7</page-range>
            <pub-id pub-id-type="pmid">26712938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vijayakumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anandan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Veeraraghavan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Specimen Collection, Processing, Culture, and Biochemical Identification of Acinetobacter spp.</article-title>
            <source>Methods Mol Biol</source>
            <year>2019</year>
            <volume>1946</volume>
            <fpage>1</fpage>
            <page-range>1-15</page-range>
            <pub-id pub-id-type="pmid">30798539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sievert</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ricks</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kallen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Limbago</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fridkin</surname>
                <given-names>S</given-names>
              </name>
              <collab>National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities</collab>
            </person-group>
            <article-title>Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">23221186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bozorgmehr</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bahrani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fatemi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ventilator-Associated Pneumonia and Its Responsible Germs; an Epidemiological Study.</article-title>
            <source>Emerg (Tehran)</source>
            <year>2017</year>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <pub-id pub-id-type="pmid">28286833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17097.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burnham</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Rojek</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Kollef</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>97</volume>
            <issue>42</issue>
            <fpage>e12782</fpage>
            <pub-id pub-id-type="pmid">30334966</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
